BCR::ABL1 fusion independently predicted a lower incidence of relapse, while MLL::AF4 independently associated with a higher risk of relapse (RFS for BCR::ABL1: p = 0.005 with HR: 0.34, 95% CI, 0.16–0.72; for MLL rearrangements: p = 0.013 with HR: 4.40, 95% CI, 1.37–14.13) after adjustment for WBC, age, and other primary aberrations in the total ALL series (Table 3B). This evidence concerns the gene BCR and acute lymphoblastic leukemia.